Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions

被引：41

作者：

Chang, Chih-Jung ^{[1
,2
,3
,4
,5
,6
]}

Chen, Chun-Bing ^{[1
,2
,3
,4
,5
,6
,7
,8
,9
,10
]}

Hung, Shuen-Iu ^{[1
,2
,3
,4
,7
]}

Ji, Chao ^{[11
]}

Chung, Wen-Hung ^{[1
,2
,3
,4
,5
,6
,7
,8
,9
,12
,13
]}

机构：

[1] Chang Gung Mem Hosp, Dept Dermatol, Taipei, Taiwan

[2] Chang Gung Mem Hosp, Drug Hypersensit Clin & Res Ctr, Taipei, Taiwan

[3] Chang Gung Mem Hosp, Dept Dermatol, Keelung, Taiwan

[4] Chang Gung Mem Hosp, Drug Hypersensit Clin & Res Ctr, Keelung, Taiwan

[5] Huaqiao Univ, Xiamen Chang Gung Hosp, Sch Med, Cent Res Lab,Dept Dermatol, Xiamen, Peoples R China

[6] Huaqiao Univ, Xiamen Chang Gung Hosp, Sch Med, Xiamen Chang Gung Allergol Consortium, Xiamen, Peoples R China

[7] Chang Gung Mem Hosp, Dept Med Res, Canc Vaccine & Immune Cell Therapy Core Lab, Taoyuan, Taiwan

[8] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[9] Chang Gung Mem Hosp, Whole Genome Res Core Lab Human Dis, Keelung, Taiwan

[10] Chang Gung Univ, Grad Inst Clin Med Sci, Taoyuan, Taiwan

[11] Fujian Med Univ, Affiliated Hosp 1, Dept Dermatol, Fuzhou, Peoples R China

[12] Tsinghua Univ, Beijing Tsinghua Chang Gung Hosp, Sch Clin Med, Dept Dermatol, Beijing, Peoples R China

[13] Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2020年 / 11卷

关键词：

drug hypersensitivity; pharmacogenetics; severe cutaneous adverse reactions; human-leukocyte antigen; T cell receptor; STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; COST-EFFECTIVENESS ANALYSIS; HLA CLASS-I; INDUCED LIVER-INJURY; HLA-B-ASTERISK-1502; ALLELE; T-CELLS; HYPERSENSITIVITY REACTIONS; JAPANESE PATIENTS; ALLOPURINOL HYPERSENSITIVITY;

D O I：

10.3389/fphar.2020.00969

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS), are idiosyncratic and unpredictable drug-hypersensitivity reactions with a high-mortality rate ranging from 10% to over 30%, thus causing a major burden on the healthcare system. Recent pharmacogenomic studies have revealed strong associations between SCAR and the genes encoding human-leukocyte antigens (HLAs) or drug-metabolizing enzymes. Some of pharmacogenetic markers have been successfully applied in clinical practice to protect patients from SCAR, such as HLA-B*15:02 and HLA-A*31:01 for new users of carbamazepine, HLA-B*58:01 for allopurinol, and HLA-B*57:01 for abacavir. This article aims to update the current knowledge in the field of pharmacogenomics of drug hypersensitivities or SCAR, and its implementation in the clinical practice.

引用

页数：11